We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
-6.99%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$309M
AUM Growth
+$9.64M
(+3.2%)
Cap. Flow
+$29.4M
Cap. Flow
% of AUM
9.51%
Top 10 Holdings %
Top 10 Hldgs %
36.34%
Holding
93
New
15
Increased
35
Reduced
30
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
EVHC
Envision Healthcare Holdings Inc
EVHC
|
+$7.87M |
| 2 |
HRC
HILL-ROM HOLDINGS, INC.
HRC
|
+$6.46M |
| 3 |
Elevance Health
ELV
|
+$5.1M |
| 4 |
WBA
Walgreens Boots Alliance
WBA
|
+$4.56M |
| 5 |
Boston Scientific
BSX
|
+$4.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Viatris
VTRS
|
+$4.58M |
| 2 |
AbbVie
ABBV
|
+$4.49M |
| 3 |
Medtronic
MDT
|
+$4.43M |
| 4 |
Zimmer Biomet
ZBH
|
+$3.96M |
| 5 |
Abbott
ABT
|
+$3.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.88% |
| 2 | Financials | 3.47% |
| 3 | Industrials | 1.36% |
| 4 | Technology | 0.14% |
| 5 | Consumer Staples | 0.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Teva Pharmaceuticals
TEVA
$36.2B
| $17.4M | 5.63% |
324,833
-5,200
| -2% | -$305K |
|
|
MNK
2
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
| $14.2M | 4.59% |
231,229
+9,700
| +4% | +$620K |
|
3
Encompass Health
EHC
$11.3B
| $13.8M | 4.46% |
459,798
+1,885
| +0.4% | +$52K |
|
|
AET
4
DELISTED
Aetna Inc
AET
| $10.7M | 3.47% |
95,215
+9,200
| +11% | +$984K |
|
|
HRC
5
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $9.93M | 3.22% |
197,424
+136,900
| +226% | +$6.46M |
|
|
6
Boston Scientific
BSX
$67.6B
| $9.91M | 3.21% |
526,698
+250,600
| +91% | +$4.4M |
|
|
7
Zimmer Biomet
ZBH
$17.8B
| $9.88M | 3.2% |
95,486
-40,891
| -30% | -$3.96M |
|
|
WBA
8
DELISTED
Walgreens Boots Alliance
WBA
| $8.97M | 2.91% |
106,514
+57,100
| +116% | +$4.56M |
|
9
UnitedHealth
UNH
$379B
| $8.96M | 2.9% |
69,506
-3,000
| -4% | -$355K |
|
10
Biogen
BIIB
$29.5B
| $8.52M | 2.76% |
32,732
+1,200
| +4% | +$317K |
|
|
STJ
11
DELISTED
St Jude Medical
STJ
| $8.02M | 2.6% |
145,882
+19,001
| +15% | +$1.04M |
|
12
Thermo Fisher Scientific
TMO
$208B
| $7.57M | 2.45% |
53,486
+11,341
| +27% | +$1.52M |
|
|
AGN
13
DELISTED
Allergan plc
AGN
| $7.37M | 2.39% |
27,500
+3,900
| +17% | +$1.12M |
|
14
Stryker
SYK
$129B
| $7.33M | 2.38% |
68,360
+12,900
| +23% | +$1.27M |
|
|
EVHC
15
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $7.31M | 2.37% |
+119,706
| New | +$7.87M |
|
|
BXLT
16
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $7.08M | 2.29% |
175,225
-44,900
| -20% | -$1.78M |
|
|
SHPG
17
DELISTED
Shire pic
SHPG
| $6.83M | 2.21% |
39,753
+24,943
| +168% | +$4.18M |
|
18
Becton Dickinson
BDX
$43.8B
| $6.83M | 2.21% |
46,083
-4,774
| -9% | -$677K |
|
19
McKesson
MCK
$99.5B
| $6.82M | 2.21% |
43,347
+11,776
| +37% | +$1.9M |
|
20
HCA Healthcare
HCA
$86.4B
| $6.41M | 2.08% |
82,180
+15,955
| +24% | +$1.11M |
|
|
SPNC
21
DELISTED
Spectranetics Corp
SPNC
| $6.28M | 2.04% |
432,726
-123,040
| -22% | -$1.7M |
|
22
Gilead Sciences
GILD
$162B
| $6.23M | 2.02% |
67,810
+25,400
| +60% | +$2.29M |
|
|
AMAG
23
DELISTED
AMAG Pharmaceuticals
AMAG
| $6.21M | 2.01% |
265,180
+154,000
| +139% | +$3.66M |
|
|
24
Elevance Health
ELV
$82.1B
| $6.06M | 1.96% |
43,624
+38,157
| +698% | +$5.1M |
|
|
25
Medtronic
MDT
$108B
| $5.39M | 1.75% |
71,866
-58,800
| -45% | -$4.43M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q1 2016 Portfolio in Review
As of Q1 2016, Endurant Capital Management held 93 positions worth $309M, up 3.2% from $299M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Endurant Capital Management deployed $29.4M of net new capital in Q1 2016, opening 15 new positions and adding to 35 existing holdings. Its largest new stake was Envision Healthcare Holdings Inc: 119,706 shares worth $7.31M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, down from 89% a quarter earlier, followed by Financials and Industrials.
On the sell side, the largest reduction was Viatris, an estimated $4.58M trimmed.
- Endurant Capital Management's largest Q1 2016 buy was Envision Healthcare Holdings Inc: 119,706 shares worth $7.31M.
- Endurant Capital Management added most to HILL-ROM HOLDINGS, INC. in Q1 2016, an estimated $6.46M increase.
- Endurant Capital Management's biggest Q1 2016 reduction was Viatris, cutting an estimated $4.58M.
- Endurant Capital Management fully exited BioDelivery Sciences International, Inc. in Q1 2016, selling an estimated $1.33M.
- Endurant Capital Management's ten largest holdings make up 36% of its $309M portfolio in Q1 2016.
- Endurant Capital Management opened 15 new positions and closed 7 in Q1 2016.
- Endurant Capital Management's portfolio value rose 3.2% quarter-over-quarter to $309M.
Based on Endurant Capital Management's 13F filing for Q1 2016, filed 16 May 2016.